Nicolas Tilmans is the cofounder and CEO of Anagenex, an AI-powered drug discovery platform. They have raised $37M in funding so far from investors such as Lux Capital, Khosla Ventures, Air Street, Menlo, and Catalio. He was previously the VP of Engineering at Lumiata. He has a PhD in Biochemistry from Stanford.

In this episode, we cover a range of topics including:
- What are small molecule drugs and why are they challenging to develop
- The founding of Anagenex
- Data generation engine
- DNA Encoded Libraries (DELs)
- Affinity Selected Mass Spectrometry
- Identifying the right targets
- What's next for AI-infused drug discovery

Nicolas's favorite books:
- Tomorrow, and Tomorrow, and Tomorrow (Author: Gabrielle Zevin)
- Letters by Abraham Lincoln (Author: Abraham Lincoln)

--------
Where to find Prateek Joshi:

Newsletter: https://prateekjoshi.substack.com 
Website: https://prateekj.com 
LinkedIn: https://www.linkedin.com/in/prateek-joshi-91047b19 
Twitter: https://twitter.com/prateekvjoshi